MYC and diffuse large B-cell lymphoma: Among 39 patients with R/R DLBCL and/or HGBCL with MYC and/or BCL2 and/or BCL6 gene rearrangements receiving co-treatment with RO6870810 and venetoclax and/or rituximab (NCT03255096), 8 CR and 7 PR were observed [122].